KR20140096373A - 폴리에틸렌글리콜이 수식된 인테그린 차단제 hm-3 및 그 응용 - Google Patents

폴리에틸렌글리콜이 수식된 인테그린 차단제 hm-3 및 그 응용 Download PDF

Info

Publication number
KR20140096373A
KR20140096373A KR1020147016557A KR20147016557A KR20140096373A KR 20140096373 A KR20140096373 A KR 20140096373A KR 1020147016557 A KR1020147016557 A KR 1020147016557A KR 20147016557 A KR20147016557 A KR 20147016557A KR 20140096373 A KR20140096373 A KR 20140096373A
Authority
KR
South Korea
Prior art keywords
tumor
once
mpeg
group
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020147016557A
Other languages
English (en)
Korean (ko)
Inventor
한메이 쉬
하이민 창
즈안 캉
Original Assignee
한메이 쉬
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한메이 쉬 filed Critical 한메이 쉬
Publication of KR20140096373A publication Critical patent/KR20140096373A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/04—Peptides being immobilised on, or in, an organic carrier entrapped within the carrier, e.g. gel, hollow fibre
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020147016557A 2011-11-21 2012-11-17 폴리에틸렌글리콜이 수식된 인테그린 차단제 hm-3 및 그 응용 Ceased KR20140096373A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2011103705299A CN102417540A (zh) 2011-11-21 2011-11-21 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用
CN201110370529.9 2011-11-21
PCT/CN2012/084788 WO2013075600A1 (zh) 2011-11-21 2012-11-17 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197020874A Division KR102106485B1 (ko) 2011-11-21 2012-11-17 폴리에틸렌글리콜이 수식된 인테그린 차단제 hm-3 및 그 응용

Publications (1)

Publication Number Publication Date
KR20140096373A true KR20140096373A (ko) 2014-08-05

Family

ID=45942198

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197020874A Active KR102106485B1 (ko) 2011-11-21 2012-11-17 폴리에틸렌글리콜이 수식된 인테그린 차단제 hm-3 및 그 응용
KR1020147016557A Ceased KR20140096373A (ko) 2011-11-21 2012-11-17 폴리에틸렌글리콜이 수식된 인테그린 차단제 hm-3 및 그 응용

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020197020874A Active KR102106485B1 (ko) 2011-11-21 2012-11-17 폴리에틸렌글리콜이 수식된 인테그린 차단제 hm-3 및 그 응용

Country Status (7)

Country Link
US (2) US20140329759A1 (enExample)
EP (1) EP2784093B1 (enExample)
KR (2) KR102106485B1 (enExample)
CN (1) CN102417540A (enExample)
AU (1) AU2012343020B2 (enExample)
IN (1) IN2014CN04482A (enExample)
WO (1) WO2013075600A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102417540A (zh) * 2011-11-21 2012-04-18 中国药科大学 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用
CN103656615B (zh) * 2013-12-11 2017-01-04 南京安吉生物科技有限公司 一种hm-3和铂类、紫杉醇类或他滨类药物在制备实体瘤药物中的用途
CN103623394A (zh) * 2013-12-11 2014-03-12 南京安吉生物科技有限公司 一种peg-hm-3和铂类、紫杉醇类或他滨类药物在制备实体瘤药物中的用途
CN103739671B (zh) * 2013-12-31 2015-08-26 郭向华 一种聚乙二醇修饰的抑制核因子-κB多肽及其应用
CN103739673B (zh) * 2013-12-31 2015-08-19 浙江元太生物科技有限公司 一种聚乙二醇修饰的抑制白介素-6多肽及其应用
CN103739669B (zh) * 2013-12-31 2015-08-26 浙江元太生物科技有限公司 一种抑制白介素-6多肽及其应用
CN103736078B (zh) * 2014-01-09 2017-12-12 南京安吉生物科技有限公司 mPEG‑HM‑3多肽冻干粉针制剂及其制备方法和用途
CN103720667B (zh) * 2014-01-09 2016-04-13 中国药科大学 Ap-25多肽冻干粉针制剂及其制备方法和用途
CN103819542A (zh) * 2014-02-28 2014-05-28 中国药科大学 一种聚乙二醇修饰及蛋白质融合表达的整合素阻断剂ap-25及其应用
CN104127378A (zh) * 2014-08-11 2014-11-05 中国药科大学 mPEG-SC20K-HM-3多肽注射液及其制备方法和用途
CN105622721A (zh) * 2015-12-16 2016-06-01 李斯文 一种聚乙二醇修饰的血管生成抑制剂hs-1及其应用
CN105646667A (zh) * 2016-04-06 2016-06-08 南京安吉生物科技有限公司 聚乙二醇修饰的血管生成抑制剂hm-1及其应用
CN108623693B (zh) * 2017-03-20 2022-03-25 徐寒梅 一种融合蛋白及其制备方法和其在制备治疗眼科疾病、抗炎、抗肿瘤药物中的应用
CN109503700A (zh) * 2017-09-14 2019-03-22 南京安吉生物科技有限公司 马来酰亚胺基团修饰的血管生成抑制剂hm-1及其应用
CN107857800B (zh) * 2017-11-09 2020-05-05 北京赛升药业股份有限公司 一种长效整合素抑制剂及其应用
CN109879969B (zh) 2017-12-06 2024-04-09 天士力生物医药股份有限公司 一种hm-3融合蛋白及其应用
CN111855876B (zh) * 2020-07-10 2023-05-02 北京赛升药业股份有限公司 一种安替安吉肽有关物质的检测方法
CN113488512A (zh) * 2021-06-23 2021-10-08 深圳市华星光电半导体显示技术有限公司 显示面板及其制备方法
CN114230676B (zh) * 2021-12-22 2024-06-11 天士力生物医药股份有限公司 重组hm-3融合蛋白及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6521593B1 (en) * 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
MXPA05005469A (es) * 2002-11-25 2005-09-08 Attenuon Llc Peptidos que inhibien angiogenesis, migracion celular, invasion celular y proliferacion celular, composiciones y usos de los mismos.
CN1314705C (zh) * 2005-06-03 2007-05-09 中国药科大学 高效抑制血管生成多肽及其制备方法和应用
KR100863060B1 (ko) * 2006-06-02 2008-10-10 베이징 선바이오 바이오테크, 코오퍼레이션, 리미티드 암 억제 활동을 하는 재조합 단백질, 그 암호화 유전자 및 재조합 단백질을 활성성분으로 포함하는 암치료용 약학적 조성물
CN102145161A (zh) * 2011-04-07 2011-08-10 中国药科大学 整合素阻断剂在制备治疗肿瘤药物中的应用
CN102178656B (zh) * 2011-05-12 2012-08-22 内蒙古奇特生物高科技（集团）有限公司 Hm-3多肽冻干粉制剂及其制备方法
CN102205110B (zh) * 2011-05-18 2014-03-26 中国药科大学 整合素阻断剂在制备治疗新生血管性眼病药物中的应用
CN102417540A (zh) * 2011-11-21 2012-04-18 中国药科大学 一种聚乙二醇修饰的整合素阻断剂hm-3及其应用
CN104127378A (zh) * 2014-08-11 2014-11-05 中国药科大学 mPEG-SC20K-HM-3多肽注射液及其制备方法和用途

Also Published As

Publication number Publication date
US20170100489A1 (en) 2017-04-13
KR102106485B1 (ko) 2020-05-04
EP2784093A1 (en) 2014-10-01
AU2012343020A1 (en) 2014-06-12
WO2013075600A1 (zh) 2013-05-30
KR20190090872A (ko) 2019-08-02
AU2012343020B2 (en) 2016-05-19
EP2784093B1 (en) 2019-10-09
IN2014CN04482A (enExample) 2015-09-04
US20140329759A1 (en) 2014-11-06
EP2784093A4 (en) 2015-08-05
CN102417540A (zh) 2012-04-18

Similar Documents

Publication Publication Date Title
KR102106485B1 (ko) 폴리에틸렌글리콜이 수식된 인테그린 차단제 hm-3 및 그 응용
BRPI0512286B1 (pt) Proteínas quiméricas inibidoras da angiogênese e o uso
WO2011011315A1 (en) POLYPEPTIDES SELECTIVE FOR AV β3 INTEGRIN CONJUGATED WITH A VARIANT OF HUMAN SERUM ALBUMIN (HSA) AND PHARMACEUTICAL USES THEREOF
US10870684B2 (en) Disintegrin variants and pharmaceutical uses thereof
KR102003422B1 (ko) 인테그린 차단제 폴리펩타이드 및 그의 응용
JP2007527206A (ja) がん治療のためのペプタボディ
Meng et al. Improved immunocompatibility of active targeting liposomes by attenuating nucleophilic attack of cyclic RGD peptides on complement 3
CN106466485B (zh) 一种具有细胞内吞介导功能的靶向配体-药物偶联体
CN105315350A (zh) 抗肿瘤血管生成多肽mPEG-Mal-Cys-AS16
Chen et al. Unleashing the potential of natural biological peptide Macropin: Hydrocarbon stapling for effective breast cancer treatment
US20230212233A1 (en) Novel mutant of recombinant ganoderma lucidum immunomodulatory protein and use thereof
CN102372770A (zh) 一种抑血管生成素、纯化方法及含有它们的药物组合物
WO2019158720A1 (en) C/ebp alpha sarna compositions and methods of use
KR101323669B1 (ko) 암세포 특이적 세포괴사 유도 및 암 소멸 효과를 나타내는 세포사 유도 융합 펩타이드
US20240424071A1 (en) Novel mutant of recombinant ganoderma lucidum immunomodulatory protein and use thereof
Pei et al. Anti-tumor activity and pharmacokinetics of AP25-Fc fusion protein
US20240082346A1 (en) Composition Comprising an Antiviral Agent and a CXCR4 Selective Antagonist and Methods For Using the Same
CN103172745A (zh) 包含免疫球蛋白Fc片段的长效人内皮抑素
CN107857800B (zh) 一种长效整合素抑制剂及其应用
BR112017003334B1 (pt) Variante de desintegrina, seu uso, composição farmacêutica e seu uso
CN107163134A (zh) 一种胸腺法新聚乙二醇聚合物、包含其的药物组合物及应用
HK1233930A1 (en) Cyclic prosaposin peptides and uses thereof
HK1233930B (en) Cyclic prosaposin peptides and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140617

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170427

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180905

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190318

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180905

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20190318

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20181105

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20190615

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20190520

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20190318

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20181105

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20180905

PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190717